Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ambrosia - Dance with me George
Little Feat - Brides Of Jesus
Eva Cassidy - Autumn Leaves
Snowblind Friend - Steppenwolf
Steely Dan - Charlie Freak
BTO - Freeways
Buffalo Springfield - Questions
Wham! - Last Christmas
There is hope yet for KW, the former CEO, and his hand picked board of directors. Sounds familiar, “The indictment alleges that these defendants conspired to defraud investors in order to line their own pockets,”
https://www.fiercebiotech.com/biotech/ex-cytodyn-ceo-amarex-ceo-hit-multiple-charges-allegedly-defrauding-investors
The Blue Nile - Stay
Wichita Lineman - Jimmy Webb
Root Boy Slim-Rich White Republican
Commander Cody and His Lost Planet Airmen
Hot Rod Lincoln
Roxy Music - Manifesto
Captain Beefheart & The Magic Band - Click Clack (Live at the Bataclan 04/15/72)
moving along, checking the boxes, all in a good way
lol, the tradition continues
3. To approve a proposed amendment to the PharmaCyte Biotech, Inc. articles of incorporation, as amended (the “PharmaCyte Charter”) to effect a reverse stock split of common stock at a ratio between 1-for-5 and 1-for-20 (or any number in between);
4. To approve a proposed amendment to the PharmaCyte Charter to increase the number of authorized shares of common stock from 33,333,334 to 133,333,334;
"Mr. Crabtree remains subject to certain continuing obligations, including a confidentiality agreement to which he is a party."
In other words no discussion of the scam to which he was party to for years and years to get the paltry severance pay (and keep a lot of shares). Slowly washing the skid mark off this company but unfortunately for remaining investors there are no skivvies
While awaiting all the exciting clinical trial data and CE removal, a few revenue generation ideas for Rik that are well within his existing stable of shams and scams
-happy hoofs for horses
-nyloxin for asses (and mules/donkeys)
-counter nerve agent for horses
-pet nerve agent away
-nyloxin for snakes (for fang pain)
-symbolically adopt a snake (serpents too)
-nyloxin suppositories (better than a snake up your ass)
-Rik's rentals (some of the best company revenues to date have been subleasing useless space)
-GoFundRik (and cut through the chase)
I am pretty sure you didn't just figure that out now
Thats what they have been missing....D'oh!
"The biotech’s board has frozen all spending on PharmaCyte programs, including pre-clinical and clinical activities, until the review is complete and a plan of action is in place."
https://www.fiercebiotech.com/biotech/pharmacyte-forced-think-outside-box-ceo-departs-amid-ongoing-clinical-hold
Hope they can claw back some ill-gotten compensation/shares
Sotyktu: Miracle Pill for Autoimmune Diseases
"Given both deucravacitinib’s new mechanism of action and its very acceptable safety profile, it has the ability to make billions of dollars for Bristol-Myers Squibb. Well, it will give immeasurably suffering patients an extra chance for healing.
For U.S. patients, the price of Sotyktu is set at $6,146 (excluding discounts and rebates) for a one-month course of treatment. A year’s worth of therapy would cost $74,000. This is one-third more than the cost of treating psoriasis with Otezla (apremilast).
According to industry forecasts, deucravacitinib sales will reach $2.4 billion annually by 2026. Peak demand for deucravacitinib will easily reach $4 billion annually."
https://biopharma.media/deucravacitinib-miracle-drug-for-autoimmune-diseases-1094/
"Sesen Bio SESN... carrying a Zacks Rank #1 (Strong Buy) at present.
Sesen Bio’s loss estimates for 2023 have narrowed from 27 cents per share to 1 cent per share over the past 30 days. Shares of Sesen Bio have declined 19% this year so far.
Earnings of Sesen Bio beat estimates in all the last four quarters, delivering a four-quarter surprise of 89.49%, on average."
https://finance.yahoo.com/news/sanofi-sny-hemophilia-drug-bla-153803082.html
Right, how else would Rik cover his lifestyle other than sucking this company dry. I do think he is going to get nipped on the loan-conversion-to-toxic-shares bit but that will take a while so carry on
I think tomorrow I will be owning a whole lot more UEC due to the UEX acquisition. Both have been berry, berry good to me!
Looks like the deck is being restacked with these statements of beneficial ownership
Just "loan" Rik some money and when he defaults take compensation in low priced toxic shares. That seems to be how most are doing it. Lots of loans for lemonade stand revenues
T Rowe Price notified me today that nphc is now restricted and I can no longer buy (as if I want anymore of this crap) and can only sell. Shady business that doesn't meet their investing standards for an equity they want to offer their customers. So I too am still holding a small bag of this crap
This is the only reason this company exists, to enrich insiders and play all these short selling money making schemes with sleazy investors. Pathetic that it is built on a bogus story about a treatment for pancreatic cancer and diabetes. But reflective of the lack of morals and ethics of the principal and his cohorts.
I am anxiously awaiting their DTRA contract for countermeasures against nerve agents...lol. And I think horses need Luxury Hoofs, standing around all day in those metal shoes. Could be a big seller at Walmart
Autonomy Places 23,000 Electric Vehicle Order With Automakers to Expand and Diversify Subscription Fleet
EV subscription fleet order valued at $1.2B
Fleet order placed for 45 electric vehicle models from 17 global automakers
Expected delivery timeline within 6 to 18 months
Order represents 1.2% of the projected U.S. electric vehicle production through the end of 2023
https://www.businesswire.com/news/home/20220809005495/en/Autonomy-Places-23000-Electric-Vehicle-Order-With-Automakers-to-Expand-and-Diversify-Subscription-Fleet
Should get into monkey pox testing/diagnosis
Item 1.01 – Entry into a Material Definitive Agreement.
On July 18, 2022, Sesen Bio, Inc. (the “Company”) announced that it has executed an asset purchase agreement (the “Asset Purchase Agreement”) with F. Hoffmann-La Roche Ltd and Hoffman-La Roche Inc. (“Roche”) pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 anti-IL antagonist monoclonal antibody technology owned by the Company (collectively, the “Intellectual Property”) for up to $70 million. As a result of the Asset Purchase Agreement, the Company’s previous license agreement with Roche dated June 10, 2016 (the “Roche License Agreement”) was terminated resulting in no further diligence, milestone or royalty payment obligations under the Roche License Agreement. Prior to the termination of the Roche License Agreement, the Company had received $50 million in upfront and milestone payments from Roche.
The Asset Purchase Agreement includes a $40 million payment to Sesen Bio upon execution of the Asset Purchase Agreement, and an additional $30 million payment to Sesen Bio that is conditioned upon Roche’s initiation of a Phase 3 clinical trial with EBI-031 for a defined indication prior to December 31, 2026.
The Company entered into the Roche License Agreement in June 2016 pursuant to which the Company granted Roche an exclusive, worldwide license to develop and commercialize the Licensed Intellectual Property. EBI-031, a humanized monoclonal antibody that potently binds IL-6 and inhibits all known forms of IL-6 cytokine signaling, is currently being developed by Roche for the potential treatment of ocular diseases.
As previously disclosed, Sesen Bio has initiated a process to review potential strategic alternatives with the goal of maximizing shareholder value. The Company believes the Asset Purchase Agreement and the associated proceeds have the potential to enable a favorable strategic transaction by increasing the range and attractiveness of strategic alternatives that the Company is able to consider.
The foregoing description of the terms of the Asset Purchase Agreement is not complete and is qualified in its entirety by reference to the Asset Purchase Agreement, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.
https://ir.sesenbio.com/node/11681/html
Item 1.01 – Entry into a Material Definitive Agreement.
On July 18, 2022, Sesen Bio, Inc. (the “Company”) announced that it has executed an asset purchase agreement (the “Asset Purchase Agreement”) with F. Hoffmann-La Roche Ltd and Hoffman-La Roche Inc. (“Roche”) pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 anti-IL antagonist monoclonal antibody technology owned by the Company (collectively, the “Intellectual Property”) for up to $70 million. As a result of the Asset Purchase Agreement, the Company’s previous license agreement with Roche dated June 10, 2016 (the “Roche License Agreement”) was terminated resulting in no further diligence, milestone or royalty payment obligations under the Roche License Agreement. Prior to the termination of the Roche License Agreement, the Company had received $50 million in upfront and milestone payments from Roche.
The Asset Purchase Agreement includes a $40 million payment to Sesen Bio upon execution of the Asset Purchase Agreement, and an additional $30 million payment to Sesen Bio that is conditioned upon Roche’s initiation of a Phase 3 clinical trial with EBI-031 for a defined indication prior to December 31, 2026.
The Company entered into the Roche License Agreement in June 2016 pursuant to which the Company granted Roche an exclusive, worldwide license to develop and commercialize the Licensed Intellectual Property. EBI-031, a humanized monoclonal antibody that potently binds IL-6 and inhibits all known forms of IL-6 cytokine signaling, is currently being developed by Roche for the potential treatment of ocular diseases.
As previously disclosed, Sesen Bio has initiated a process to review potential strategic alternatives with the goal of maximizing shareholder value. The Company believes the Asset Purchase Agreement and the associated proceeds have the potential to enable a favorable strategic transaction by increasing the range and attractiveness of strategic alternatives that the Company is able to consider.
The foregoing description of the terms of the Asset Purchase Agreement is not complete and is qualified in its entirety by reference to the Asset Purchase Agreement, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.
https://ir.sesenbio.com/node/11681/html
They need someone on the board with the mission of rooting out both financial and technical scams. Unfortunately that would put everyone out of a job since both are scams in pmcb's case. At least they could recoup the cash value though so probably worth it
"we intend to provide stockholders the option to select a different path for the future of their Company and to allow their collective voice be heard at the upcoming annual meeting scheduled for August 25, 2022."
Thinking liquidate for cash value to preserve whatever they can at a loss before KW and his cronies steal the rest of the cash. Scam
Ken Waggoner must think shareholders and Iroquois Capital are idiots....or more likely an FU attitude as he has set it up to hold all the cards. His reponse is a joke. The company and program are a scam. Let's have some laughs:
We Have a Strong Plan to Maximize Shareholder Value - 90 percent or more pps loss for all shareholders; each and every one other than a couple traders that bought in the last couple months (you will also lose eventually, bet on it). Iroquois is maybe 50 percent loss. The unscrupulous balls to make such an out right false statement. Zero plans conveyed to generate any value here at all
We Have Accelerated the Timeline to Commence our Clinical Trial - What a joke. KW assumes you all think the FDA's IND acceptance is inevitable. There is little to zero chance in the FDA lifting the clinical hold. Besides, what patient would sign up for this scam, unproven treatment?
We Have Instituted a Share Repurchase Program - So he is willing to pay shareholders a giant percentage less for their stock than what they purchased it for? That is a deal for carnival geeks. And you know he doesn't want to give away any cash that he can possibly put in his pocket. This only benefits him if he finds some idiot to buy the whole crap company for their cash value
We Value Communication with Our Shareholders and Will Institute Quarterly Conference Calls - Total BS, he has promised before and never been on time and never conveyed any information worth anything other than fodder for The Onion
We Expect to Further Strengthen Our Diverse Board of Individuals Who Have Strong Scientific, Clinical and Capital Markets Experience - No reputable individual will join this scam. Only complete replacement of all existing director/officer scammers makes sense but the company is based on a scam technology so that will never happen. Literally nobody in biotech cares
We Have Entered into New Executive Compensation Agreements with Our Executives to Align Their Compensation with Corporate Goals - Translated that means they will up their pay and drain the piggy bank faster before this goes under
Concluding Remarks - If you believe all of that you are an idiot for investing and we will gladly take your money. We have more scams to implement and continue to line our pockets with your stupid cash
Seeking director nominations of individuals with little regard for their personal reputation. Must have extensive unscrupulous business experience